The nm23 gene was isolated as a metastasis suppressor gene that exhibits low expression in high-level metastatic cancer cells. Its gene is related to the prognosis of acute myelogenous leukemia (AML) and non-Hodgkin's lymphoma (NHL). In this study, we examined the expression of nm23-H1 protein on the lymphoma cell surface of NHL. In 28 of 108 cases (25.9%), we observed Ն20% of cell surface nm23-H1 protein expression and expression was especially high in peripheral T cell lymphomas and extranodal NK/T cell lymphomas. We also observed a significant correlation between serum nm23-H1 level and cell surface nm23-H1 expression levels. In patients with high levels of cell surface nm23-H1 expression, overall and progression-free survival rates were significantly lower than those in patients with low surface nm23-H1 expression levels. When surface nm23-H1 and serum nm23-H1 were combined, patients with high levels of both exhibited a poorer prognosis than patients with a high level of one or the other. These results indicate that in addition to serum nm23-H1, cell surface nm23-H1 may be used as a prognostic factor in planning a treatment strategy. The nm23-H1 protein appears to be intimately related to biological aggressiveness of lymphoma and, therefore, might be a molecular target of NHL treatment.
Introduction
The first nm23 gene was isolated on the basis of its reduced expression in highly metastatic murine melanoma cell lines, as compared with their nonmetastatic counterparts, and has therefore been proposed as a metastatic suppressor gene. 1 Subsequently, high homology between nm23 proteins and nucleoside diphosphate kinases (NDPK) has been identified in a number of species. 2 We found that a differentiation inhibitory factor purified from conditioned medium of a differentiation-resistant mouse myeloid leukemia cell line was identical to the nm23 protein. 3, 4 In humans, eight nm23 isotypes (nm23-H1, nm23-H2, DR-nm23, nm23-H4, nm23-H5, nm23-H6, nm23-H7 and nm23-H8) have been identified to date. 5 Immunohistochemical studies have reported that patients with high-grade non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma exhibit significantly higher levels of nm23-H1 expression than do those with low-grade NHL. 6 Recently, we established an enzyme-linked immunosorbent assay (ELISA) technique to determine the serum level of nm23-H1 protein. We previously reported that serum levels of nm23-H1 in aggressive NHL and acute myelogenous leukemia (AML) were significantly higher than those in controls, and that high nm23-H1 levels correlated with poor prognosis in both aggressive NHL and AML. [7] [8] [9] In a collaborative study between many institutions involving a large number of patients, we found that serum nm23-H1 was an important independent prognostic factor in NHL for diffuse large B cell lymphoma (DLBCL) and peripheral T cell lymphoma (PTCL). 8 We also examined four distinct risk groups defined by the widely used clinical international prognostic index (IPI) and demonstrated that when serum nm23-H1 protein levels are high, prognosis is poor in all four risk groups. Given these results, measurement of nm23-H1 protein may be useful in the treatment method selection process. Whether such serum nm23-H1 protein is directly produced by lymphoma cells is unclear, but its production appears to reflect the prognosis of lymphoma. In this study, to examine the clinical significance of nm23-H1 protein on the surface of lymphoma cells, we studied the relationships of surface nm23-H1 to serum nm23-H1 and other cell surface markers by flow cytometry measurement and tracked the subsequent survival rates.
Materials and methods

Patients
We measured cell surface nm23-H1 expression from February 1999 to March 2000 in a consecutive series of 108 patients with untreated NHL (62 men and 46 women; median age, 68 years; age range, 22-78 years) whose clinical course was being managed by the lymphoma treatment study group in Japan. The cases were classified morphologically according to the REAL schema 10 as defined elsewhere with or without adjunctive immunohistochemical and molecular studies. Of these 108 patients with NHL, 79 presented with B cell neoplasms and 29 with T cell neoplasms. Of the 79 patients with B cell neoplasms, three had B cell chronic lymphocytic leukemia (CLL), three had mucosa-associated lymphoid tissue (MALT), five had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), and 55 had DLBCL. Of the 29 patients with T cell neoplasms, 18 had PTCL, two had anaplastic large cell lymphoma (ALCL), six had extranodal NK/T cell lymphoma (NK/T), and three had adult T cell leukemia/lymphoma (ATLL). Clinical staging was performed according to the Ann Arbor classification system. 11 Evaluation included a complete history and physical examination, chest roentgenography, bone marrow aspiration and biopsy, computed tomography of the chest, abdomen and pelvis, hemogram and differential counts and routine biochemistry tests. Laparotomy was not performed for staging. The IPI was determined in all NHL cases. 12 Patients with aggressive NHL and disseminated disease were treated with cyclophosphamide, vincristine, prednisolone, bleomycin, doxorubicin and procarbazine (COP-BLAM), 13 cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), 14 
Flow cytometry for human cell surface nm23-H1
The compound 7-amino-actinomycin D (7AAD) was purchased from Sigma Chemical (St Louis, MO, USA). The drug was diluted in phosphate-buffered saline (PBS) as a 25 g/ml stock solution, which was stored at 4°C. FITC-conjugated monoclonal anti-nm23-H1 antibody was purchased from Seikagaku Kougyo (Tokyo, Japan). PE-conjugated anti-Leu4 (CD3), Leu3a (CD4), Leu2a (CD8), LeuM5 (CD11c), Leu11a (CD16), and Leu12 (CD19) were purchased from Becton Dickinson (Cowley, UK) and CD5, CD10 and CD56 were purchased from BD PharMingen (San Diego, CA, USA). FITC-and PE-conjugated murine IgG monoclonal antibodies of unrelated specificities were always used as controls. Fresh tissues were transported immediately in RPMI 1640 solution to the flow cytometry laboratory. Lymphocytes were disaggregated and released from solid tissue by injection of RPMI 1640 solution. Up to 1 × 10 6 cells were pelleted, incubated with 5 l of 7AAD solution (final 1 g/ml), 50 l of FITC-conjugated monoclonal antibody, and PE-conjugated monoclonal antibody for 30 min at 4°C while protected from light, and then pelleted by centrifugation. The supernatant was removed, and the cells were resuspended in Cell FIX solution (Becton Dickinson). Two-color flow cytometric immunophenotyping was performed on a FACS Caliber instrument (Becton Dickinson) by collecting 10 000 ungated list-mode events, selecting an appropriate lymphocyte gate on the combination of forward and side scatter, and analyzing cells with the most appropriated lymphocyte gate. The 7AAD solution was used to eliminate dead cells. Percentage surface nm23-H1 corresponds to % of cells expressing nm23 at their surface.
ELISA for human nm23-H1
We previously established an ELISA procedure to determine nm23-H1 protein levels in the serum. [7] [8] [9] Briefly, 96-well plates (Corning, Corning, NY, USA) were coated with a monoclonal anti-nm23-H1 antibody (Seikagakukougyo, Tokyo, Japan), washed four times with PBS, and incubated with 25% Block Ace solution (Dainihon Seiyaku, Osaka, Japan). Serum samples were diluted two-fold with PBS and 50 l aliquots were added to the wells. After incubation at room temperature for 1 h, the wells were washed four times with PBS containing 0.05% Tween 20 (T-PBS). Samples were then incubated at room temperature for 1 h with a polyclonal anti-nm23-H1 antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), washed four times with T-PBS, and incubated with alkaline phosphatase-conjugated anti-rabbit IgG (BioRad Lab, Richmond, CA, USA). After four washes with T-PBS, alkaline phosphatase activity was detected with diethanolamine as a subLeukemia strate and an alkaline phosphatase-detecting kit (BioRad Lab). The reaction was stopped with 50 l of 0.4 N NaOH. Absorbance was measured at 405-415 nm with a correction wavelength of 620-630 nm using a microplate reader.
Statistical analysis
The patients' characteristics were compared using chi-square tests. Judgment criteria used for the analysis were progressionfree survival (PFS) and overall survival (OS). Progression was defined as a progression of the lymphoma in nonresponding patients or partial response patients, a relapse for complete response patients, or death from any cause without progression. PFS was calculated as the time from randomization to the first progression. Patients who did not experience a progression at the time of analysis were censored at the most recent date of disease assessment or at the stop date if the most recent date was later. OS was measured from the date of randomization to the date of death, regardless of cause. Patients who were still living at the time of analysis were censored at the most recent date of disease assessment or at the stop date if the most recent date was later. Survival analysis was performed according to the Kaplan-Meier method. 15 The statistical significance of differences in survival was determined by the log-rank and generalized Wilcoxon's tests. 16 Differences between groups were evaluated by the Mann-Whitney U test (nonparametric analysis), 17 and P < 0.05 was taken to indicate significance. Figure 1 shows a case of DLBCL, in which both CD19 and nm23-H1 markers were positive but markers CD3, CD5, CD16 and CD56 were negative. The results are the representative patterns of a case of surface nm23-H1-positive DLBCL, and we also obtained similar results from another three patients (data not shown). Figure 2 shows a case of extranodal NK/T cell lymphoma in which both CD56 and nm23-H1, and CD16 and nm23-H1 markers were positive but markers CD3, CD5 and CD19 were negative. The results are the representative patterns of a case of surface nm23-H1 positive extranodal NK/T cell lymphoma, and we also obtained similar results from another three patients (data not shown). In 28 of 108 patients (25.9%), Ն20% expression of cell surface nm23-H1 was observed. On the other hand, the nm23-H1 expression was observed in 12 of 55 patients with DLBCL (21.8%), and in eight of 18 patients with PTCL (44.4%). We found a significant correlation between serum nm23-H1 levels and cell surface nm23-H1 expression (r = 0.531, P < 0.0001) (Figure 3a) . A slightly correlation was observed between serum LDH level and cell surface nm23-H1 expression (Figure 3b) , although a significant correlation was found between serum nm23-H1 and LDH levels (r = 0.464, P < 0.0001) (data not shown). No correlation was observed with soluble interleukin-2 receptor (sIL-2R). No significant correlation was found between cell surface nm23-H1 expression and CD19 (Figure 4a ) or CD3 (Figure 4b ), while significant correlations were seen with CD16 (r ϭ 0.389, P = 0.000031) (Figure 4c ) and CD56 (r = 0.37, P = 0.00008) (Figure 4d ). We also examined CD4, CD5, CD8, CD10 and CD23 but did not find any significant correlation with cell surface nm23-H1 (data not shown).
Results
Correlation between nm23-H1 expression and serum parameters or cell surface markers
Studies of cell surface nm23-H1 protein expression level in each histopathological type
As shown in Table 1 , the cell surface nm23-H1 expression level (mean ± s.d. was 2.96 ± 1.14% in reactive lymphoadenopathy (including viral infection and systemic lupus erythematosis) (n = 7). In addition, we examined cell surface nm23-H1 expression level for each histopathological type. Compared with reactive lymphoadenopathy, no statistically significant difference was found for all B cell lymphomas; however, among T cell lymphomas, the expression was sig- nificantly higher in PTCL (26.9 ± 21.02%, P < 0.01) and NK/T cell lymphoma (46.04 ± 37.77%, P < 0.001). Thus, nm23-H1 appears to be related to the biological aggressiveness of lymphoma.
Relationship between cell surface nm23-H1 protein levels and clinicopathological data in aggressive lymphoma
The relationship between cell surface nm23-H1 expression levels and clinicopathological factors was investigated in 81 patients with aggressive NHL (Table 2) . When the median nm23-H1 expression was used as the threshold value, a high expression level of nm23-H1 before treatment was strongly associated with poor prognostic features such as elevated serum LDH level and Ann Arbor stage (P < 0.05 for all comparisons, Mann-Whitney U test or Kruskal-Wallis test). The assessment of each risk group classified according to IPI revealed significantly higher expression of nm23-H1 in the high-intermediate (H-I) and high (H) risk groups than in the low (L) and low-intermediate (L-I) risk groups (P = 0.01, Kruskal-Wallis test). Complete remission was achieved in 65 (80.2%) of the 81 patients, and the median surface level of Relationship between serum nm23-H1 and surface nm23-H1 expression (a) and between LDH and surface nm23-H1 expression (b). nm23-H1 in these patients was 11.3% at the time of diagnosis. This value was significantly lower than that in patients who showed a partial remission or failed to respond (18.5%, P = 0.0326), suggesting a close relationship between the surface level of nm23-H1 and therapeutic responsiveness.
Figure 4
Relationship between CD19 expression and surface nm23-H1 expression (a), CD3 expression and surface nm23-H1 expression (b), CD16 expression and surface nm23-H1 expression (c), and CD56 expression and surface nm23-H1 expression (d).
Leukemia
Correlation of cell surface nm23-H1 with OS and PFS
The 81 patients with aggressive NHL were divided into two groups on the basis of cell surface nm23-H1 expression levels, with a threshold of 40%. Then the OS rate was calculated for patients falling into each 10% interval from an nm23-H1 expression of 20% upward. OS rates were significantly different for patients having nm23-H1 expression levels higher than 40% compared with those having levels of 40% or lower. Consequently, an nm23-H1 level of 40% was taken as the threshold value. The 2-year OS rate for the high (n = 8) nm23-H1 group was 20.0% and for the low (n = 73) nm23-H1 group was 76.2% (P = 0.0008 for the log-rank test and P = 0.0014 for generalized Wilcoxon's test) (Figure 5a) , with PFS values of 23.4% for the high group and 46.0% for the low group (P = 0.02 for the log-rank test and P = 0.0068 for generalized Wilcoxon's test) ( Figure. 5b ). This indicated that the prognosis of aggressive lymphoma was poor when the cell surface nm23-H1 level was 20% or higher.
We investigated the possibility of obtaining a more accurate prognosis by combining cell surface nm23-H1 and serum nm23-H1 measurements. The combination of cell surface nm23-H1 (40%) and serum nm23-H1 (80 ng/ml) is shown in Figure 6 . We divided the 81 patients into three groups on the basis of both cell surface nm23-H1 and serum nm23-H1: group A (n = 64) had low levels of both factors, group B (n = 11) had a low level of only one factor, and group C (n = 6) had no low levels. The 2-year OS rate for group A was 78.6%, group B was 49.7%, and group C was 0% (Figure 6a ). An analysis of survival probability among these groups showed that group C had a significantly shorter survival period than the other groups (P = 0.0001). The 2-year PFS rate for group A was 50.1%, group B was 29.5%, and group C was 0%, and the prognosis for group C was again significantly worse than those for the other groups (P = 0.0001 for the log-rank test and P = 0.003 for generalized Wilcoxon's test) (Figure 6b ). These results indicate that the combination of cell surface nm23-H1 and serum nm23-H1 may be a useful prognostic factor. 
Discussion
As shown in the Introduction section, eight distinctly different isotypes of nm23 gene family have now been identified in humans. 5 Among this family, only nm23-H1 and nm23-H2 have been extensively studied in human cancers. The proteins encoded by nm23-H1 and nm23-H2 show 88% amino acid sequence homology and the genes locate on the same region of chromosome 17q21 in tandem. [18] [19] [20] [21] Its gene products encode NDPK which belongs to a family of genes highly conserved in eukaryotes. The nm23-H1 and nm23-H2 are completely identical to NDPK-A and NDPK-B, respectively. 21 There is an inverse relationship between nm23-H1 expression and metastasis in cancers of the breast, ovaries, cervix, gastric epithelia, hepatocellular carcinoma and melanomas. 2 However, overexpression of nm23-H1 is indicative of poor patient prognosis in neuroblastomas, and mutations of nm23-H1 proteins are detected in advanced neuroblastoma. 22, 23 Therefore, nm23-H1 is implicated in the regulation of metastasis in a variety of human cancers. The nm23-H1 was overexpressed Overall survival (a) and progression-free survival (b) curves of patients with aggressive lymphoma. The eight patients with high surface nm23-H1 expression had a worse prognosis than the 73 patients with low surface nm23-H1 expression.
in various hematological neoplasms including AML, acute lymphoblastic leukemia, myelodysplastic syndrome, and chronic myelogenous leukemia (CML) in blastic crisis, than in normal blood cells. 24 The progression of CML was accompanied by the overexpression of nm23-H1 and nm23-H2 mRNA. This increase in nm23-H1 was observed not only in leukemia, but also in malignant lymphoma. It has been reported that high-grade NHL and Hodgkin's lymphoma exhibited significantly higher levels of nm23-H1 expression than low-grade NHL. 6 We previously reported that the prognosis of AML cases in which nm23-H1 mRNA is highly expressed was poor. 24 However, measurement of nm23-H1 mRNA before treatment is time-consuming and we thus sought a Classification of patients with aggressive non-Hodgkin's lymphoma according to the two important independent prognostic factors. Overall survival (a) and progression-free survival (b) curves are shown. Group A (n = 64): low serum nm23-H1 (<80 ng/ml) and low surface nm23-H1 expression (<40%). Group B (n = 11): low serum nm23-H1 (<80 ng/ml) and high surface nm23-H1 expression (>40%) or high serum nm23-H1 (>80 ng/ml) and low surface nm23-H1 expression (<40%). Group C (n = 6): high serum nm23-H1 (>80 ng/ml) and high surface nm23-H1 expression (>40%). more rapid method that would require only a small blood sample, and established a system in which nm23-H1 protein in blood is measured by ELISA. In a previous study, we measured the serum nm23-H1 protein levels by ELISA in 102 patients with AML and found that serum nm23-H1 protein levels were high in patients with AML compared with controls, and that patients with high levels exhibited a poor prognosis. 9 We had previously reported that serum nm23-H1 levels in patients with NHL were also significantly high compared with controls and that the prognosis for high-level cases was poor. 7 However, no proof exists that serum nm23-H1 is directly produced by lymphoma cells.
The expression of nm23-H1 or nm23-H2 proteins on the cell surface of leukemia cell lines and lymphoma cell lines has been reported. 25 Willems et al 26 have recently reported that they could not demonstrate nm23 on the surface of any normal hematopoietic cells including lymphocytes. In this study, the cell surface nm23-H1 of patients with NHL was measured by flow cytometry; 25.9% of cases were positive (Ն20% expression) and, specifically, more positive cases were seen in PTCL and NK/T cell lymphomas. The expression of cell surface nm23-H1 was high in NK/T cell lymphomas compared with B cell lymphomas and we reported similar results for serum nm23-H1. 8 A significant correlation was found between cell surface nm23-H1 and serum nm23-H1, which may suggest the possibility of cell surface nm23-H1 being liberated into serum. We also identified a significant correlation between serum nm23-H1, but not cell surface nm23-H1, and Leukemia certain other prognostic factors, namely LDH or sIL-2R. Therefore, serum nm23-H1 might be produced not only as a result of nm23-H1 separating from the cell surface, but also with the aid of T cells or NK cells. However, the molecular mechanism by which nm23 protein is expressed on the cell surface remains unclear. This protein might be expressed via intracellular transportation after its synthesis or shed from cells and then attached to the cell surface. Moreover, as nm23 possesses an RGD sequence, recognized to be characteristic of the integrin family, it may possess a secretory function, similar to cytokinins, in addition to a function as an adhesion ligand. 27 However, it is more likely that cytoplasmic nm23-H1 is released from cells (after lyses) and is then captured by other cells at their surface, since nm23-H1 displays no leader peptide. Moreover, it would also prove very interesting to know whether nm23-H1, expressed on cell surfaces, is intact (full-length) or fragmented. Further studies could clarify this point.
In clinical observation studies and nm23-H1 cell surface studies, surface nm23-H1 was found to be related to LDH level and stage in a manner similar to serum nm23-H1, suggesting that surface nm23-H1 may also be related to lymphoma dissemination or tumor burden. In the cases of complete remission, expression was low, possibly related to treatment reactivity. Contemporary NHL treatment includes assessment with the IPI, proposed in 1993 as a prognosis forecasting model. 12 The IPI abstracts five prognostic factors: age (>60 years old), clinical stage (III, IV), performance status (2-4), serum LDH (>normal), and number of extranodal lesions (>1). Depending on the number of factors, IPI then divides cases into four groups: L risk (0-1), L-I risk (2), H-I risk (3) and H risk (4) (5) . Recently, many biological prognostic factor studies have been performed to seek a replacement for IPI or another indicator that may be used in combination with IPI. In one such study, the genetic expression of DLBCL was systematically analyzed using cDNA microarrays, and two DLBCL types that were clearly distinguishable at the molecular level were identified (one with germinal center B-like RNA expression and the other with activated B-like RNA expression). Comparison of survival rates revealed that the prognosis of activated B-like DLBCL was significantly poorer than that of germinal center B-like DLBCL; the same result was obtained when the comparison was restricted to low-risk clinical patients. 28 Shipp and her colleagues, who identified a B-aggressive lymphoma (BAL) gene in DLBCL, found that the level of expression of this gene among high-risk DLBCL patients was significantly higher than that among low-risk DLBCL patients and indicated that this gene could be used as a novel prognostic factor. 29 We are planning to investigate further the relationship between nm23 and these biological prognostic factors.
We have reported that serum nm23-H1 levels, which can be measured from only a small amount of serum, can be used as a prognostic factor for aggressive NHL (not only for DLBCL but also for PTCL). In this study of cell surface nm23-H1 expression, prognosis was poor in cases that showed Ն40% expression and poorer in cases in which the expression of both cell surface nm23-H1 and serum nm23-H1 was high. Therefore, the combination of two markers appears useful for determining the poorer prognosis group in need of front-line peripheral blood stem cell transplant treatment, given that prognosis is poor in the cases where expression of either serum nm23-H1 or cell surface nm23-H1 is high. Therefore, the expression of nm23-H1 can be measured in not only intracellular RNA and serum protein, but also on the cell surface.
As each one of these nm23-H1 parameters is a prognostic factor, nm23-H1 is thus a fundamental prognostic factor for lymphoma. In addition, cell surface nm23-H1 expression can be easily measured simultaneously with lymphoma surface marker by flow cytometry, making it a potentially useful prognostic factor for deciding treatment strategy for lymphoma. The possibility of new treatment methods that target nm23-H1 on the surface of lymphomas remains to be explored.
